CD274 and neoplasm: In cervical cancer, pembrolizumab was approved in 2018 by the FDA as a single agent in patients with recurrent or metastatic cervical cancer with disease progression after chemotherapy and tumor expression of programmed death-ligand 1 (PD-L1) (combined positivity score (CPS) ≥ 1), but it is not approved in Europe [25].